| A controlled trial of a human papillomavirus type 16 vaccine LA Koutsky, KA Ault, CM Wheeler, DR Brown, E Barr, FB Alvarez, ... New England Journal of Medicine 347 (21), 1645-1651, 2002 | 2576 | 2002 |
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases SM Garland, M Hernandez-Avila, CM Wheeler, G Perez, DM Harper, ... New England Journal of Medicine 356 (19), 1928-1943, 2007 | 2486 | 2007 |
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial DM Harper, EL Franco, C Wheeler, DG Ferris, D Jenkins, A Schuind, ... The lancet 364 (9447), 1757-1765, 2004 | 2378 | 2004 |
| Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre … LL Villa, RLR Costa, CA Petta, RP Andrade, KA Ault, AR Giuliano, ... The lancet oncology 6 (5), 271-278, 2005 | 2348 | 2005 |
| Sustained efficacy up to 4· 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial DM Harper, EL Franco, CM Wheeler, AB Moscicki, B Romanowski, ... The Lancet 367 (9518), 1247-1255, 2006 | 2259 | 2006 |
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a … J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ... The Lancet 374 (9686), 301-314, 2009 | 2070 | 2009 |
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of … J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ... The Lancet 369 (9580), 2161-2170, 2007 | 1676 | 2007 |
| Improved amplification of genital human papillomaviruses PE Gravitt, CL Peyton, TQ Alessi, CM Wheeler, F Coutlee, A Hildesheim, ... Journal of clinical microbiology 38 (1), 357-361, 2000 | 1400 | 2000 |
| Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double … M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ... The lancet oncology 13 (1), 89-99, 2012 | 895 | 2012 |
| Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis M Drolet, É Bénard, N Pérez, M Brisson, H Ali, MC Boily, V Baldo, ... The Lancet 394 (10197), 497-509, 2019 | 839 | 2019 |
| Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined … EA Joura, S Leodolter, M Hernandez-Avila, CM Wheeler, G Perez, ... The Lancet 369 (9574), 1693-1702, 2007 | 837 | 2007 |
| Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method PE Gravitt, CL Peyton, RJ Apple, CM Wheeler Journal of clinical microbiology 36 (10), 3020-3027, 1998 | 800 | 1998 |
| American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors D Saslow, PE Castle, JT Cox, DD Davey, MH Einstein, DG Ferris, ... CA: a cancer journal for clinicians 57 (1), 7-28, 2007 | 742 | 2007 |
| Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial C Mao, LA Koutsky, KA Ault, CM Wheeler, DR Brown, DJ Wiley, ... Obstetrics & Gynecology 107 (1), 18-27, 2006 | 712 | 2006 |
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in … DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... The Journal of infectious diseases 199 (7), 926-935, 2009 | 696 | 2009 |
| Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 LL Villa, KA Ault, AR Giuliano, RLR Costa, CA Petta, RP Andrade, ... Vaccine 24 (27-28), 5571-5583, 2006 | 679 | 2006 |
| Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide … HU Bernard, SY Chan, MM Manos, CK Ong, LL Villa, H Delius, CL Peyton, ... Journal of Infectious Diseases 170 (5), 1077-1085, 1994 | 638 | 1994 |
| Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis … CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ... The lancet oncology 13 (1), 100-110, 2012 | 621 | 2012 |
| Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective T Yamada, MM Manos, J Peto, CE Greer, N Munoz, FX Bosch, ... Journal of virology 71 (3), 2463-2472, 1997 | 593 | 1997 |
| A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade … M Schiffman, PE Castle, D Maucort-Boulch, CM Wheeler, ... The Journal of infectious diseases 195 (11), 1582-1589, 2007 | 554 | 2007 |
